Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–312. https://doi.org/10.1016/S0140-6736(18)31948-2.

Article  PubMed  Google Scholar 

de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95(1):322–7. https://doi.org/10.1073/pnas.95.1.322.

Article  PubMed  PubMed Central  Google Scholar 

Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573–85. https://doi.org/10.1016/s0092-8674(00)80949-6.

Article  CAS  PubMed  Google Scholar 

Fronczek R, Lammers GJ, Balesar R, et al. The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome. J Clin Endocrinol Metab. 2005;90(9):5466–70. https://doi.org/10.1210/jc.2005-0296.

Article  CAS  PubMed  Google Scholar 

Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18(23):9996–10015. https://doi.org/10.1523/JNEUROSCI.18-23-09996.1998.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435(1):6–25. https://doi.org/10.1002/cne.1190.

Article  CAS  PubMed  Google Scholar 

Chieffi S, Carotenuto M, Monda V, et al. Orexin system: the key for a healthy life. Front Physiol. 2017;8:357. https://doi.org/10.3389/fphys.2017.00357.

Article  PubMed  PubMed Central  Google Scholar 

Tsujino N, Sakurai T. Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci. 2013;7:28. https://doi.org/10.3389/fnbeh.2013.00028.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahler SV, Moorman DE, Smith RJ, et al. Motivational activation: a unifying hypothesis of orexin/hypocretin function. Nat Neurosci. 2014;17(10):1298–303. https://doi.org/10.1038/nn.3810.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nollet M, Leman S. Role of orexin in the pathophysiology of depression: potential for pharmacological intervention. CNS Drugs. 2013;27(6):411–22. https://doi.org/10.1007/s40263-013-0064-z.

Article  CAS  PubMed  Google Scholar 

Khairuddin S, Aquili L, Heng BC, et al. Dysregulation of the orexinergic system: a potential neuropeptide target in depression. Neurosci Biobehav Rev. 2020;118:384–96. https://doi.org/10.1016/j.neubiorev.2020.07.040.

Article  CAS  PubMed  Google Scholar 

Feng P, Vurbic D, Wu Z, et al. Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine. J Psychopharmacol. 2008;22(7):784–91. https://doi.org/10.1177/0269881106082899.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nocjar C, Zhang J, Feng P, et al. The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience. 2012;218:138–53. https://doi.org/10.1016/j.neuroscience.2012.05.033.

Article  CAS  PubMed  Google Scholar 

Arendt DH, Ronan PJ, Oliver KD, et al. Depressive behavior and activation of the orexin/hypocretin system. Behav Neurosci. 2013;127(1):86–94. https://doi.org/10.1037/a0031442.

Article  CAS  PubMed  Google Scholar 

Kim TK, Kim JE, Park JY, et al. Antidepressant effects of exercise are produced via suppression of hypocretin/orexin and melanin-concentrating hormone in the basolateral amygdala. Neurobiol Dis. 2015;79:59–69. https://doi.org/10.1016/j.nbd.2015.04.004.

Article  CAS  PubMed  Google Scholar 

Jalewa J, Wong-Lin K, McGinnity TM, et al. Increased number of orexin/hypocretin neurons with high and prolonged external stress-induced depression. Behav Brain Res. 2014;272:196–204. https://doi.org/10.1016/j.bbr.2014.05.030.

Article  CAS  PubMed  Google Scholar 

Rainero I, Ostacoli L, Rubino E, et al. Association between major mood disorders and the hypocretin receptor 1 gene. J Affect Disord. 2011;130(3):487–91. https://doi.org/10.1016/j.jad.2010.10.033.

Article  CAS  PubMed  Google Scholar 

Cengiz M, Karaj V, Kocabasoğlu N, et al. Orexin/hypocretin receptor, Orx1, gene variants are associated with major depressive disorder. Int J Psychiatry Clin Pract. 2019;23(2):114–21. https://doi.org/10.1080/13651501.2018.1551549.

Article  CAS  PubMed  Google Scholar 

Brundin L, Björkqvist M, Petersén A, et al. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol. 2007;17(9):573–9. https://doi.org/10.1016/j.euroneuro.2007.01.005.

Article  CAS  PubMed  Google Scholar 

Brundin L, Björkqvist M, Träskman-Bendz L, et al. Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. J Affect Disord. 2009;113(1–2):179–82. https://doi.org/10.1016/j.jad.2008.04.011.

Article  CAS  PubMed  Google Scholar 

Salomon RM, Ripley B, Kennedy JS, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry. 2003;54(2):96–104. https://doi.org/10.1016/s0006-3223(02)01740-7.

Article  CAS  PubMed  Google Scholar 

Pålhagen S, Qi H, Mårtensson B, et al. Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson’s disease and major depression. J Neurol. 2010;257(4):524–32. https://doi.org/10.1007/s00415-009-5353-6.

Article  CAS  PubMed  Google Scholar 

Schmidt FM, Brügel M, Kratzsch J, et al. Cerebrospinal fluid hypocretin-1 (orexin A) levels in mania compared to unipolar depression and healthy controls. Neurosci Lett. 2010;483(1):20–2. https://doi.org/10.1016/j.neulet.2010.07.038.

Article  CAS  PubMed  Google Scholar 

Schmidt FM, Arendt E, Steinmetzer A, et al. CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res. 2011;190(2–3):240–3. https://doi.org/10.1016/j.psychres.2011.06.004.

Article  CAS  PubMed  Google Scholar 

Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol. 2014;171(2):283–93. https://doi.org/10.1111/bph.12261.

Article  CAS  PubMed  Google Scholar 

Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265–74. https://doi.org/10.1212/WNL.0b013e31827688ee.

Article  CAS  PubMed  Google Scholar 

Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461–71. https://doi.org/10.1016/S1474-4422(14)70053-5.

Article  CAS  PubMed  Google Scholar 

Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136–48. https://doi.org/10.1016/j.biopsych.2014.10.003.

Article  CAS  PubMed  Google Scholar 

Herring WJ, Connor KM, Snyder E, et al. Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials. J Clin Sleep Med. 2016;12(9):1215–25. https://doi.org/10.5664/jcsm.6116.

Article  PubMed  PubMed Central  Google Scholar 

Murphy P, Moline M, Mayleben D, et al. Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, double-blind, placebo-controlled study. J Clin Sleep Med. 2017;13(11):1289–99. https://doi.org/10.5664/jcsm.6800.

Article  PubMed  PubMed Central  Google Scholar 

Rosenberg R, Murphy P, Zammit G, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2(12):e1918254. https://doi.org/10.1001/jamanetworkopen.2019.

Article  PubMed  PubMed Central  Google Scholar 

Yardley J, Kärppä M, Inoue Y, et al. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Med. 2021;80:333–42. https://doi.org/10.1016/j.sleep.2021.01.048.

Article  PubMed  Google Scholar 

Zammit G, Dauvilliers Y, Pain S, et al. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 2020;94(21):e2222–32. https://doi.org/10.1212/WNL.0000000000009475.

Article  CAS  PubMed  Google Scholar 

Xue T, Wu X, Chen S, et al. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis. Sleep Med Rev. 2022;61: 101573. https://doi.org/10.1016/j.smrv.2021.101573.

Article  CAS  PubMed  Google Scholar 

Kan CC, Breteler MH, Zit